Denosumab-bnht (Conexxence/Bomyntra, Fresenius Kabi) received FDA approval based on findings from two comparative clinical studies. One study assessed the pharmacokinetics, pharmacodynamics and ...

March 27, 2025--(BUSINESS WIRE)--Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence ® (denosumab-bnht) and Bomyntra ® (denosumab-bnht ...